
Jab duo could extend life by up to 16 years and de-age the brain - but are you brave enough to take it?
The injections involve the 'anti-ageing molecule' klotho, a type of protein that is naturally produced by the body.
Levels of klotho, named after the mythological Greek figure Clotho, who spun the thread of human life, naturally decline as we get age.
This process occurs at the same time we start experiencing age-related maladies like weaker bones, loss of muscle mass and declining cognitive abilities.
Now, Spanish scientists have developed a klotho-based treatment that both increased levels of the protein in mice and boosted the lifespan of the rodents by a fifth.
The experts said this is the equivalent of adding an extra 16 years to an 80 year-old human's lifespan.
Not only did these mice live longer they showed improved muscle strength, bone density and brain function.
While further research is needed before the treatment can be trialled on humans, the authors of the new study claim it could make a massive contribution to improving the ageing process.
In the study, published in the journal Molecular Therapy, experts from the University of Barcelona used a specially modified virus to deliver klotho into the mice's cells.
This harmless virus carried the biological blueprints for cells to produce the protein, enabling the mice to boost their klotho levels over a long period.
Mice were given the virus via two injections—one into a vein in the body and the other directly into the brain.
This enabled it to bypass the natural barrier that normally protects the vital organ and allowed scientists to examine klotho's effect on the brain.
In total, three groups of mice were tested.
One received the treatment at six months of age, another got the dose at 12 months, and a final group of six month old mice got a placebo to act as a control.
Male mice injected at 12 months were found to live the longest (31.5 months on average), a fifth longer than the control group who only lasted 26.3 months.
The average mouse lives for roughly 12 to 18 months.
The researchers noted that klotho levels were the highest among the animals injected at one year old.
Researchers also tested the mice on their physical fitness and found those in the treatment group performed better in experiments measuring coordination and muscle strength.
Tissue analysis showed mice on klotho had less internal scarring on their muscles and were generally more muscular.
Female mice on the treatment, however, did not see the same lifespan extension due to severe health complications that the scientists said were not related to the treatment.
However they did develop stronger bones.
Analysis of brain tissue also showed mice of both sexes showed signs they were developing new neurons in the hippocampus, an area of the brain closely linked to learning.
This suggests the treatment could combat age-related dementia.
Currently the implications for using the treatment in people remain limited.
Mice aren't humans, and many drugs and treatments that have shown promise on rodents have failed to replicate this success when trialled on people.
Also of note is that many of the tissue samples used in the analysis only came from a limited number of rodents, between three and four, which could limit the results.
However, Joan Roig-Soriano, an expert in neuroscience and author of the new study, said techniques that can provide klotho to humans are already available.
'We now have viral vectors that can reach the brain after being administered intravenously, which would make it easier to safely transfer this therapy to humans,' he said.
'Another option would be to administer the protein directly as a drug instead of using viral vectors, but we still need to find an efficient way to deliver it and ensure it reaches the target organs,' he said.
Previous research has shown klotho can improve brain function in old primates and 'de-age' the brains of mice by decades.
Klotho was originally discovered by Japanese researchers who found that the amount produced by mice could affect how long the rodents lived.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
6 minutes ago
- Daily Mail
Physiotherapist reveals why you should NEVER cross your legs on a flight
It can be difficult to get comfortable during plane journeys, with small seats and little leg room there is often not much room for movement. Many passengers cross their legs on flights, but AXA Health physiotherapist Bethany Tomlinson has warned against the common seating position. According to research, more than one in 10 adults in the UK experience joint issues. However, this pain could be worsened by long periods of inactivity sitting on aeroplanes. Bethany explains the risks that can come with sitting cross-legged during a flight. She warns: 'Avoid crossing your legs in your plane seat as this will impact blood flow and increase the risk of developing deep vein thrombosis (DVT).' Instead, the expert advises keeping legs elevated and choosing different relaxing positions. 'If there's a footrest under the seat in front of you, use this to keep your legs slightly elevated,' she adds. 'Make sure to relax your shoulders and support your back by sitting back into the plane seat whilst you wait.' To the millions of Brits jetting off this summer, Bethany urges travellers to prepare for the journey to avoid causing strain on joints. One in three Brits experience stiffness in their knees, and lack of movement or staying in the same position can only worsen this. Bethany says: 'Catching flights this summer could turn into an endurance test for our joints, so prepare for every flight like it could be long-haul. 'Knowing how to position your body and doing exercises when seated to keep your joints moving is essential.' Another way to ease joint discomfort is by standing in a certain position, Bethany explains. She adds: 'When standing up, shift weight between your feet, keep knees slightly bent and do light stretches to avoid too much pressure on your lower body.' For longer flights, Bethany shares what routine passengers should keep to in order to ensure their joints are healthy. Bethany warns passengers: 'Avoid crossing your legs in your plane seat as this will impact blood flow and increase the risk of developing deep vein thrombosis (DVT).' (stock) 'Flyers need to move their body every 1-2 hours on flights to keep joints mobilised. 'Being in the same position for hours can lead to stiff and swollen joints, particularly the knees, ankles and hips. 'Seated exercises whilst in the air will help boost circulation, and reduce the risk of DVT, a common type of blood clot that can form during long periods of sitting.' The physiotherapist shared a range of mobilising exercises that passengers can easily do from their plane seat, including neck stretches, shoulder rolls and knee hugs.


The Guardian
2 hours ago
- The Guardian
Treatment that can double bladder cancer survival rates available to 1,000 patients in England
More than 1,000 patients living with bladder cancer in England will be eligible for a treatment which can double survival rates from the disease. In England, 18,000 people are diagnosed with bladder cancer each year, and only about 10% of people with stage 4 bladder cancer will survive five years or more after they are diagnosed. The treatment, enfortumab vedotin with pembrolizumab, has been approved for use on the NHS from Thursday. About 1,250 patients across the country to be offered the therapy, which has been described by NHS bosses as one of the 'most hopeful advances in decades'. Clinical trials of the drug have shown that people with bladder cancer that has spread (metastasised) live up to twice as long when given the combination antibody treatment when compared with those given normal chemotherapy. One trial also found that almost 30% of patients had no detectable traces of cancer in their body following treatment with enfortumab vedotin and pembrolizumab, compared with only 12.5% with chemotherapy. Prof Peter Johnson, NHS England's national clinical director for cancer, said that the treatment is 'one of the most hopeful advances in decades for people with bladder cancer'. He added: 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' The therapy works by enfortumab vedotin directly targeting the cancer cells and killing them, while pembrolizumab, an immunotherapy drug, helps the immune system recognise and fight the remaining cancer cells. Life expectancy for people with bladder cancer which has metastasised is usually only just over a year, but this new therapy increased survival for people with this stage of the disease by more than one year. Jeannie Rigby, the chief executive of Action Bladder Cancer UK, said the charity, 'bladder cancer patients and their families welcome this much-needed, step forward in treatments available for this hard-to-treat cancer. 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available. It's also of importance that this treatment can mean these patients can experience a better quality of life with less hard to tolerate side effects.'


The Independent
2 hours ago
- The Independent
Health warning as Covid cases surge
Covid cases among hospital patients in the UK have risen by almost a third in a fortnight, sparking concerns of a new wave. The positivity rate for respiratory symptoms in hospitals increased from 5.8 per cent on 26 July to 7.6 per cent on 10 August. Virologists warn that this rise reinforces the virus's continued circulation and potential for spread, especially with people returning to work and school, and cooler weather. Experts acknowledge the difficulty in accurately assessing community infection rates due to reduced testing, though further increases are expected. The government's autumn Covid vaccine programme will offer booster jabs to 13 million fewer people, excluding those aged 65-74, pregnant women, and individuals with certain chronic conditions. New Covid wave warning as cases in hospital patients soar by 31% in a fortnight